Memphasys Ltd Eyes European Market with New Strategies
Company Announcements

Memphasys Ltd Eyes European Market with New Strategies

Memphasys Ltd (AU:MEM) has released an update.

Memphasys Ltd, a pioneering Australian biotechnology firm, is inviting shareholders to a webinar to share updates on its Felix System clinical trials, which are nearing completion. The company is eyeing a quicker entry into the European market with a fast-tracked regulatory strategy. Additionally, Memphasys has embarked on a 3-year equine study expected to yield commercial results within a year.

For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskMemphasys Ltd Issues New Unquoted Loan Options
TipRanks Australian Auto-Generated NewsdeskMemphasys Ltd Expands with New ASX Securities Issuance
TipRanks Australian Auto-Generated NewsdeskMemphasys Bolsters Financial Position with $1.857M Capital Raise
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App